ETCTN Trials by Disease/ Treatment Area: Breast Cancer

**Breast Cancer**

- **Triple negative breast cancer (TNBC)**
  - Locally advanced/ metastatic TNBC

- **Hormone receptor positive (HR+)**
  - Locally advanced/ metastatic ER+ and/or PR+/HER2-
  - Locally advanced/ metastatic ER+/HER2-

- **PN or HR+**
  - With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)
  - Bone metastatic breast cancer (TNBC or ER+ and/or PR+)

- **HER2 positive**
  - HER2+ PIK3CA mutation, PTEN mutation or PTEN loss

**TN or HR**

- **Non HER2 positive with BRCA mutation**
- **PTEN or PIK3CA mutation (TNBC or ER+/HER2-)**
- **With residual cancer burden (TNBC or ER+ and/or PR+, HER2-BC)**
- **Bone metastatic breast cancer (TNBC or ER+ and/or PR+)**

**NOTE:** *No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: February 17, 2020*